Advertisement

Brustkrebs und Östrogentherapie nach der Menopause in zwei Seniorengemeinden bei Los Angeles

  • Ronald K. Ross
  • Thomas M. Mack
  • Annlia Hill
  • Veeba R. Gerkins
  • Herman Menck
Part of the Medizinische Informatik und Statistik book series (MEDINFO, volume 7)

Zusammenfassung

Aufgrund der Information über bekannte Risikofaktoren des Brustkrebs, über Tierexperimente und über Studien der Hormonspiegel in Gruppen mit hohem und niedrigem Risiko ist die Meinung weit verbreitet, daß die hypophysären und gonadalen Hormone, insbesondere Östrogen, bei der Pathogenese des Brustkrebs eine Rolle spielen. Frauen, die Östrogen nach der Menopause bekommen, tragen also möglicherweise ein Risiko für die Entwicklung von Brustkrebs. Wir berichten hier über die Methodologie für eine laufende Fall-Kontroll-Studie in zwei Seniorengemeinden im Bereich Los Angeles, die angelegt wurde, um die prozeduralen Fehler früherer Studien zu überwinden. Eine allererste grobe Analyse der Daten, basierend auf 41 Fällen und 86 Kontrollen, läßt vermuten, daß Frauen, die in der Menopause Östrogen benutzen, insgesamt kein erhöhtes Risiko einer Brustkrebsentwicklung aufweisen. Aber es zeigt sich ein sehr komplexes Bild des Risikos je nach Dosierung und Benutzungsdauer, das einen schützenden Effekt für Frauen mit niedriger kumulativer Dosis möglich erscheinen läßt, aber ebenso ein mäßig erhöhtes Risiko für Frauen mit hoher kumulativer Dosis.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Arellano, M. G.; Linden, G.; Dunn, J.E.: Cancer patterns in Alameda County, California. Brit J Cancer 26 (1972) 473–482CrossRefGoogle Scholar
  2. 2.
    Backwinkel, K.; Jackson, A.S.: Some features of breast cancer and thyroid deficiency. Cancer 17 (1964) 1174–1176CrossRefGoogle Scholar
  3. 3.
    Brecher, P.I., Wotiz, H.H.: Competition between estradiol and estriol for end organ receptor proteins. Steriods 9 (1967) 431–437CrossRefGoogle Scholar
  4. 4.
    Bulbrook, R.D., Hayward, J.L., Spicer, C.C. et al.: A comparison between the urinary steroid excretion of normal women and women with advanced breast cancer. Lancet 2 (1962) 1235–1240CrossRefGoogle Scholar
  5. 5.
    Burch, J.G., Byrd, B.F.: Effects of long-term administration of estrogens on the occurence of mammary cancer in women. Ann Surg 174 (1971) 414–418CrossRefGoogle Scholar
  6. 6.
    Casagrande, J.; Gerkins, V.; Henderson, B.E. et al.: Exogenous estrogens and breast cancer in women with natural menopause. J Natl Cancer Inst 56 (1976) 839–841Google Scholar
  7. 7.
    Craig, T.J., Comstock, G.W., Geiser, P.B.: Epidemiologic comparison of breast cancer patients with early and late onset of malignancy and general population controls. J Natl Cancer Inst 53 (1974) 1577–1581Google Scholar
  8. 8.
    Cutler, S.J.; Christine, B.; Barclay, T.H.C.: Increasing incidence and decreasing mortality rates of breast cancer. Cancer 28 (1971) 1376–1380CrossRefGoogle Scholar
  9. 9.
    Cutts, J.H.; Nobel, R.L.: Estrone-induced mammary tumors in the rat. Cancer Res 24 (1964) 1116–1123Google Scholar
  10. 10.
    Edmondson, H.A.; Henderson, B.; Benton, B.: Liver-cell adenomas associated with use of oral contraceptives. New Engl J Med 294 (1976) 470–472CrossRefGoogle Scholar
  11. 11.
    Geist, S.H.; Walter, R.I.; Salmon, U.J.: Are estrogens carcinogenic in the human female? Amer J Obstet Gynec 42 (1941) 242–248Google Scholar
  12. 12.
    Goodman, L.S.; Gilman, A.(eds): The Pharmacological Basis of Therapeutics. New York: McMillan Company 1970, 1538–1548Google Scholar
  13. 13.
    Grace, M.; Gaudette, L.A.; Burns, P.E.: The increasing incidence of breast cancer in Alberta 1953–1973. Cancer 40 (1977) 358–363CrossRefGoogle Scholar
  14. 14.
    Henderson, B.E.; Gerkins, V.; Rosario, I. et al.: Elevated serum levels of estrogen and prolactin in daughters of patients with breast cancer. New Engl J Med 293 (1975) 790–795CrossRefGoogle Scholar
  15. 15.
    Henderson, B.E.; Pike, M.C.; Gerkins, V.R. et al.: The hormonal basis of breast cancer: elevated plasma levels of estrogen, prolactin, and progesterone. Presented at the meeting “Origins of Human Cancer”, Cold Spring Harbor, New York, 1976Google Scholar
  16. 16.
    Henderson, B.E.; Powell, D.; Rosario, I. et al.: An epidemiologic study of breast cancer. J Natl Cancer Inst 53 (1974) 609–614Google Scholar
  17. 17.
    Henneman, P.H.; Wallach, S.: The use of androgens and estrogens and their metabolic effects: a review of the prolonged use of estrogens and androgens in postmenopausal and senile osteoporosis. Arch Intern Med 100 (1957) 715–723CrossRefGoogle Scholar
  18. 18.
    Herbst, A.L.; Ulfelder, H.; Paskanzer, D.C.: Adenocarcinoma of the vagina. New Engl J Med 284 (1971) 878CrossRefGoogle Scholar
  19. 19.
    Hertz, R.: The estrogen-cancer hypothesis. Cancer 38, Supplement July 1976, 534–538CrossRefGoogle Scholar
  20. 20.
    Hisserich, J.C.; Martin, S.P., Henderson, B.E.: An areawide cancer reporting network. Publ Hlth Rep 90 (1975) 15–17CrossRefGoogle Scholar
  21. 21.
    Hoover, R.; Gray, L.; Cole, P. et al.: Menopausal estrogens and breast cancer. New Engl J Med 295 (1976) 401–405CrossRefGoogle Scholar
  22. 22.
    Kapdi, C.C.; Wolfe, J.M.: Breast cancer: relationship to thyroid supplements for hypothyroidism. JAMA 236 (1976) 1124–1127CrossRefGoogle Scholar
  23. 23.
    Kwa, H.G.; Engelsman, E. De Jong-Bakken, M. et al.: Plasma prolactin in human breast cancer. Lancet 1 (1974) 433–435CrossRefGoogle Scholar
  24. 24.
    Lacassagne, A.: Essai d’une hormone thyreotrope en vue de modifier l’appurition de 1’adenocarcinome mammaire chez la souris. Comp. rend Soc de Biol 130 (1939) 591Google Scholar
  25. 25.
    Leis, H.A.: Endocrine prophylaxis of breast cancer with cyclic estrogen and progesterone. Int Surg 45 (1966) 496–503Google Scholar
  26. 26.
    Lemon, H.M.: Endocrine influences on human mammary formation: a critique. Cancer 23 (1969) 781–790CrossRefGoogle Scholar
  27. 27.
    Lemon, H.M.; Wotiz, H.H.; Parsons, L. et al.: Reduced estriol excretion in patients with breast cancer prior to endocrine therapy. JAMA 196 (1966) 112–120CrossRefGoogle Scholar
  28. 28.
    Lipschutz, A.; Varga, L.: Tumorgenic powers of stilbestrol and follicular hormones. Lancet 1 (1940) 541–543CrossRefGoogle Scholar
  29. 29.
    Mack, T.M.; Martin, S.; Menck, H.: Unpublished data. LAC/USC Cancer Surveillance Program, Los Angeles County, CaliforniaGoogle Scholar
  30. 30.
    Mack, T.M.; Pike, M.C.; Henderson, B.E. et al.: Estrogens and endometrial cancer in a retirement community. New Engl J Med 294 (1976) 1262–1267CrossRefGoogle Scholar
  31. 31.
    MacMahon, B.; Cole, P.; Brown, J.: Etiology of human breast cancer: a review. J Natl Cancer Inst 50 (1973) 21–42Google Scholar
  32. 32.
    MacMahon, B.; Cole, P.; Brown, J. et al.: Oestrogen profiles of Asian and North American women. Lancet 2 (1971) 900–902CrossRefGoogle Scholar
  33. 33.
    Monson, R.R.; Yen, S.; MacMahon, B.: Chronic mastitis and carcinoma of the breast. Lancet 2 (1976) 224–226CrossRefGoogle Scholar
  34. 34.
    Muhlbrook, O.; Boot, L.M.: The mode of action of ovarian tumors in the induction of mammary cancer in mice. Biochem Pharmacol 16 (1967) 627–630CrossRefGoogle Scholar
  35. 35.
    Mustacchi, P.; Gordon, G.S.: Frequency of cancer in estrogen-treated osteoporotic women: In Breast Cancer. The Second Biennial Louisiana Cancer Conference, New Orleans, Jan. 22–23.1958 (Segaloff, A. ed.), St. Louis: C.V. Mosby Co. 1958, 163–169Google Scholar
  36. 36.
    Poortman, J.; Thijssen, J.H.H.; Schwartz, F.: Androgen production and conversion to estrogens in normal post-menopausal women and in selected breast cancer patients. J Clin Endocrin Metab 37 (1973) 101–109CrossRefGoogle Scholar
  37. 37.
    Rotti, K.J.; Stevens, J.; Watson, D. et al.: Estriol concentrations in plasma of normal, non-pregnant women. Steroids 25 (1975) 807–812CrossRefGoogle Scholar
  38. 38.
    Schleyer-Saunders, E.: The management of the menopause. Med Press 244 (1960) 337Google Scholar
  39. 39.
    Segaloff, A.: The role of the ovary in estrogen production in mammary cancer in the rat. Cancer Res 34 (1974) 2708–2710Google Scholar
  40. 40.
    Sherman, B.M., Korenman, S.G.: Inadequate corpus luteum function: a pathophysiological interpretation of human breast cancer epidemiology. Cancer 33 (1974) 1306–1312CrossRefGoogle Scholar
  41. 41.
    Siiteri, P.K.; Schwartz, B.E.; MacDonald, P.C.: Estrogen receptors and the estrone hypothesis in relation to endometrial and breast cancer. Gynec Oncology 2 (1974) 228–238CrossRefGoogle Scholar
  42. 42.
    Stadel, B.V.; Weiss, N.: Characteristics of menopausal women: A survey of King and Pierce counties in Washington, 1973–1974. Amer J Epidem 102 (1975) 209–216Google Scholar
  43. 43.
    Stavraky, K.; Emmons, S.: Breast cancer in premenopausal and postmenopausal women. J Natl Cancer Inst 53 (1974) 647–654Google Scholar
  44. 44.
    de Waard, F.: Breast cancer incidence and nutritional status with particular reference to body weight and height. Cancer Res 35 (1975) 3351–3356Google Scholar
  45. 45.
    Welsch, C.W.; Jenkins, T.W.; Meites, J.: Increased incidence of mammary tumors in the female rat grafted with multiple pituitaries. Cancer Res 30 (1970) 1024–1039Google Scholar
  46. 46.
    Wilson, C.A.: The role of estrogen and progesterone in breast and genital cancer. JAMA 182 (1962) 327–331CrossRefGoogle Scholar
  47. 47.
    Ziel, H.K.; Finkle, W.D.: Increased risk of endometrial carcinoma among users of conjugated estrogens. New Engl J Med 293 (1975) 1167–1170CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1978

Authors and Affiliations

  • Ronald K. Ross
  • Thomas M. Mack
  • Annlia Hill
  • Veeba R. Gerkins
  • Herman Menck

There are no affiliations available

Personalised recommendations